Biogen Inc
(MIL:1BIIB)
€
208.8
-6.3 (-2.97%)
Market Cap: 30.32 Bil
Enterprise Value: 35.79 Bil
PE Ratio: 27.92
PB Ratio: 2.13
GF Score: 55/100 - Q1 2024 Biogen Inc Earnings Call TranscriptApr 24, 2024€189.4 (+4.07%)Earnings
- Q4 2023 Biogen Inc Earnings Call TranscriptFeb 13, 2024€213 (-5.42%)Earnings
- Biogen Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Biogen Inc at Evercore ISI HealthCONx Conference TranscriptNov 28, 2023
- Q3 2023 Biogen Inc Earnings Call TranscriptNov 08, 2023Earnings
- Biogen Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 11, 2023
- Biogen Inc to Acquire Reata Pharmaceuticals Inc Call TranscriptJul 28, 2023
- Q2 2023 Biogen Inc Earnings Call TranscriptJul 25, 2023Earnings
- Q1 2023 Biogen Inc Earnings Call TranscriptApr 25, 2023Earnings
- Biogen Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2023
- Biogen Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Biogen Inc Earnings Call TranscriptFeb 15, 2023Earnings
- Biogen Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- SAGE Therapeutics Inc and Biogen Inc to Discuss Potential Commercialization Plans for Zuranolone TranscriptDec 06, 2022
- Biogen Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptDec 01, 2022
- Q3 2022 Biogen Inc Earnings Call TranscriptOct 25, 2022Earnings
- Biogen Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Biogen Inc Earnings Call TranscriptJul 20, 2022Earnings
- Q1 2022 Biogen Inc Earnings Call TranscriptMay 03, 2022Earnings
- Biogen Inc at Stifel CNS Days (Virtual) TranscriptMar 28, 2022
- Biogen Inc at Cowen Health Care Conference (Virtual) TranscriptMar 07, 2022
- Q4 2021 Biogen Inc Earnings Call TranscriptFeb 03, 2022Earnings
- Biogen Inc Analyst Q&A Call TranscriptJan 13, 2022
- Biogen Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Biogen Inc Engage and Emerge Trials at CTAD Call TranscriptNov 11, 2021
- Q3 2021 Biogen Inc Earnings Call TranscriptOct 20, 2021Earnings
- Biogen Inc to Present at the American Neurological Association Virtual Meeting TranscriptOct 17, 2021
- Biogen Inc Investor Day TranscriptSep 21, 2021
- Biogen Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Q2 2021 Biogen Inc Earnings Call TranscriptJul 22, 2021Earnings
- Biogen Inc at SVB Leerink CNS Forum (Virtual) TranscriptJun 29, 2021
- Biogen Inc to Discuss the Approval of ADUHELM Call TranscriptJun 08, 2021
- Biogen Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Q1 2021 Biogen Inc Earnings Call TranscriptApr 22, 2021Earnings
- Biogen Inc at the Stifel 3rd Annual CNS Day TranscriptMar 31, 2021
- Biogen Inc Evaluation of aducanumab safety in early Alzheimer's disease at AD/PD TranscriptMar 13, 2021
- Biogen Inc Evaluation Of Aducanumab Efficacy And Safety In Early Alzheimer's Disease Discussion at AD/PD Conference Call TranscriptMar 13, 2021
- Biogen Inc Live Discussion of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD TranscriptMar 10, 2021
- Biogen Inc Pre-Recorded Presentation of Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE and ENGAGE at AD/PD TranscriptMar 10, 2021
- Biogen Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 01, 2021
- Biogen Inc Aducanumab Webinar Update TranscriptFeb 23, 2021
- Q4 2020 Biogen Inc Earnings Call TranscriptFeb 03, 2021Earnings
- Biogen Inc Corporate Call TranscriptJan 14, 2021
- Biogen Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Biogen Inc Conference Call to Discuss Collaboration with SAGE Therapeutics Inc TranscriptNov 30, 2020
- SAGE Therapeutics Inc Conference Call to Discuss Collaboration with Biogen Inc TranscriptNov 30, 2020
- Biogen Inc Aducanumab EMBARK study design and Q&A at CTAD 2020 TranscriptNov 04, 2020
- Q3 2020 Biogen Inc Earnings Call TranscriptOct 21, 2020Earnings
- Biogen Inc Emerging Science: Alzheimers, Migraine, ALS, CIDP TranscriptSep 23, 2020
- Biogen Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 14, 2020
- Biogen Inc Aducanumab Phase 3 Topline Results at AAIC (encore presentation and Q&A) TranscriptJul 29, 2020
- Q2 2020 Biogen Inc Earnings Call TranscriptJul 22, 2020Earnings
- Biogen Inc at Leerink CybeRx Series CNS Forum TranscriptJun 23, 2020
- Biogen Inc Annual Shareholders Meeting TranscriptJun 03, 2020
- Biogen Inc to Discuss Aducanumab Phase 3 Topline Results at AAN Presentation TranscriptMay 18, 2020
- Q1 2020 Biogen Inc Earnings Call TranscriptApr 22, 2020Earnings
- Biogen Inc Aducanumab Phase 3 Topline Results TranscriptApr 02, 2020
- Biogen Inc at Cowen HealthCare Conference TranscriptMar 02, 2020
- Q4 2019 Sangamo Therapeutics Inc Earnings and Collaboration Agreement with Biogen Inc Call TranscriptFeb 28, 2020
- Q4 2019 Biogen Inc Earnings Call TranscriptJan 30, 2020Earnings
- Biogen Inc at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Biogen Inc Investor Q&A Call TranscriptDec 05, 2019
- Biogen Inc Aducanumab Phase 3 Topline Results TranscriptDec 05, 2019
- Biogen Inc at Evercore HealthCONx Conference TranscriptDec 03, 2019
- Q3 2019 Biogen Inc Earnings and Update on Aducanumab Call TranscriptOct 22, 2019
- Biogen Inc at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Q2 2019 Biogen Inc Earnings Call TranscriptJul 23, 2019Earnings
- Biogen Inc Annual Shareholders Meeting TranscriptJun 19, 2019
- Biogen Inc Webcast on ALS Portfolio Corporate Call TranscriptJun 05, 2019
- Biogen Inc at Sanford C Bernstein Strategic Decisions Conference TranscriptMay 30, 2019
- Q1 2019 Biogen Inc Earnings Call TranscriptApr 24, 2019Earnings
- Biogen Inc at Cowen Health Care Conference TranscriptMar 11, 2019
- Biogen Inc to Acquire Nightstar Therapeutics PLC to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology Call TranscriptMar 04, 2019
- Q4 2018 Biogen Inc Earnings Call TranscriptJan 29, 2019Earnings
Biogen Inc at JPMorgan Healthcare Conference Transcript
Jan 08, 2024 / 07:15PM GMT
Release Date Price:
€243.8
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
So good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat today with Chris Viehbacher, who joined Biogen as CEO, I guess, a little bit over a year ago. So Chris, happy New Year. Thanks for joining us.
Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director
Happy New year to you too, Chris.
Questions & Answers
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst
Yes. So I think we were talking before. About a year ago, we were sitting in these same 2 seats. You had just come on as CEO. So I would love to start the conversation with just your reflections on how the last year has gone, anything that surprised you at a positive or negative in the CEO seat? And we'll kick off from there.
Christopher A. Viehbacher
Biogen Inc. - President, CEO & Director
Well, thanks, Chris. Yes,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)